<DOC>
	<DOCNO>NCT02853136</DOCNO>
	<brief_summary>To investigate influence fluvoxamine pharmacokinetics BI 409306</brief_summary>
	<brief_title>Influence Fluvoxamine Pharmacokinetics BI 409306</brief_title>
	<detailed_description />
	<mesh_term>Fluvoxamine</mesh_term>
	<criteria>Inclusion criterion : Healthy male female subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age 18 50 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Male female subject meet follow criterion start screen 30 day trial completion regard adequate contraception : Nonhormonal intrauterine device combination condom Sexually abstinent Surgically sterilise ( include hysterectomy ) A vasectomised sexual partner ( vasectomy least 1 year prior enrolment ) Postmenopausal , define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level FSH 40 U/L estradiol 30 ng/L confirmatory ) Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 100 140 mmHg , diastolic blood pressure outside range 60 90 mmHg , pulse rate outside range 50 85 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Use drug within 30 day prior administration trial medication might reasonably influence result trial ( incl . QT/QTc interval prolongation ) Participation another trial investigational drug administer within 60 day prior plan administration trial medication Current smoker exsmoker quit smoke less 30 day prior screen Alcohol abuse ( consumption 20 g per day females 30 g per day male ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m male repeatedly great 470 m female ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study History major bleed event ( e.g . gastric bleeding , intracranial haemorrhage ) base investigator 's judgement Intake drug may interfere fluvoxamine monoamine oxidase inhibitor , tizanidine . Intake hormonal contraception ovary hormone replacement therapy female subject Subjects medical history suicidal behaviour History increase intraocular pressure Positive pregnancy test , pregnancy plan become pregnant within 30 day study completion Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>